Nanosonics Limited (ASX: NAN) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Nanosonics Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Nanosonics Limited (ASX: NAN)
Latest News

A beautiful ocean vista is shown with a woman whose back is to the camera holding her arms up in triumph as she stands at the top of a rock feeling thrilled that ASX 200 shares are reaching multi-year high prices today
Share Gainers

Here are the top 10 ASX 200 shares today

Is this why ASX 200 retailers outperformed on Tuesday?

Read more »

The words short selling in red against a black background
Share Market News

Here are the 10 most shorted ASX shares

Short sellers are currently targeting these ASX shares...

Read more »

trophy depicting top 10, asx 200 shares
Share Gainers

Here are the top 10 ASX 200 shares today

Mining shares took the backseat on Thursday.

Read more »

stylised silhouette of a bear on financial graph background
Share Market News

Here are the 10 most shorted ASX shares

Short sellers are currently targeting these ASX shares...

Read more »

A beautiful ocean vista is shown with a woman whose back is to the camera holding her arms up in triumph as she stands at the top of a rock feeling thrilled that ASX 200 shares are reaching multi-year high prices today
Share Gainers

Here are the top 10 ASX 200 shares today

Banks and tech led the market on Tuesday.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Bigtincan, Nanosonics, Origin, and Tyro shares are sinking today

These ASX shares are having a tough start to the week...

Read more »

most shorted shares webjet
Share Market News

Here are the 10 most shorted ASX shares

Short sellers are currently targeting these ASX shares...

Read more »

most shorted ASX shares
Share Market News

Here are the 10 most shorted ASX shares

Short sellers are currently targeting these ASX shares...

Read more »

Happy healthcare workers in a labs
Healthcare Shares

3 best-performing ASX 200 healthcare shares in November

Fisher & Paykel led the way last month with a 17% gain.

Read more »

A group of science or medical professionals cheering good news in the lab.
Share Gainers

Here are the top 10 ASX 200 shares today

Guess which healthcare stock led the index on Tuesday.

Read more »

A woman wearing dark clothing and sporting a few tattoos and piercings holds a phone and a takeaway coffee cup as she strolls under the Sydney Harbour Bridge which looms in the background.
Defensive Shares

Buy now: Experts name 2 ASX 200 companies essential to Aussie life

When the economy is slowing down, you need to look for businesses that consumers just can't live without.

Read more »

The words short selling in red against a black background
Share Market News

Here are the 10 most shorted ASX shares

Short sellers are currently targeting these ASX shares...

Read more »

Frequently Asked Questions

No, Nanosonics Ltd does not pay dividends at this stage.

Nanosonics Ltd listed on the ASX on 17 May 2007.

NAN ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Nanosonics Limited

Nanosonics Ltd (ASX: NAN) is an Australian healthcare company specialising in infection prevention.

The company has developed and commercialised an automated disinfection technology, the trophon device. Nanosonics says it represents the first major innovation in high-level disinfection for ultrasound probes in more than two decades and is fast becoming the global standard of care for ultrasound probe disinfection. The company also manufactures and distributes other related technologies.

Nanosonics is based in Sydney with sales offices in the US and Europe.

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
26 Feb 2026 Sarah Butler Buy 15,000 $50,977
On-market trade.
18 Dec 2025 Michael Kavanagh Issued 405,184 $1,653,150
Issue of securities. 18,58,192 Rights
11 Dec 2025 Michael Kavanagh Issued 59,233 $257,071
Issue of securities. 1,453,008 Rights
04 Dec 2025 Michael Kavanagh Exercise 66,380 $274,813
Conversion of securities. 13,93,775 rights
04 Dec 2025 Michael Kavanagh Buy 66,380 $274,813
Conversion of securities.
23 Sep 2025 Michael Kavanagh Buy 109,685 $462,870
Conversion of securities.
23 Sep 2025 Michael Kavanagh Exercise 109,685 $462,870
Conversion of securities. 1,460,155 - Rights
17 Sep 2025 Gerard Dalbosco Buy 12,558 $51,231
On-market trade. Average $4.08 per share, as per announcement

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Larry Marshall Non-Executive Director Oct 2023
Dr Marshall is a technology innovator, physicist and business leader. Until July 2023, Dr Marshall was Chief Executive of CSIRO for eight and a half years. During his 26 years in the US, Dr Marshall co-founded six companies in a range of markets including medical device which went public. Over the past 30 years, he has served as CEO/ MD of six companies, and Chairman of four. He was MD, then co-Chairman of Arasor which he took public in 2006. In 2007, Dr Marshall became MD of Southern Cross Venture Partners, a Silicon Valley VC firm specializing in Australian innovation. He has been a director of 20 private sector boards in Australia and the US, including boards of two companies that were subsequently publicly listed. He is a member of the Innovation & Development and the People & Culture, Safety Committee.
Mr Michael Kavanagh Chief Executive OfficerManaging Director Jul 2012
Mr Kavanagh has 30 years of international commercial experience in the healthcare sector, Michael has a record of driving innovation, operational excellence, and sustainable growth across the medical device and pharmaceutical industries. Prior to joining Nanosonics, Michael served on the Executive Team of Cochlear Ltd for more than a decade as Senior Vice President of Global Marketing. He is a member of the Innovation & Development Committee.
Ms Marie Elizabeth McDonald Non-Executive Director Oct 2016
Ms McDonald brings with her a background in corporate and commercial law, having practiced for many years as a partner at Ashurst. Ms McDonald was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia (2012 to 2013) and was a member of the Australian Takeovers Panel from 2001 to 2010. She is a member of the Risk committee and the Chair of the People & Culture, Safety Committee.
Mr Steven Andrew Sargent Non-Executive DirectorNon-Executive Chairman Jul 2016
Mr Sargent career included 22 years at General Electric, where he received multi-industry, international experience leading businesses in industries including healthcare, energy and financial services across the US, Europe and Asia Pacific. Mr Sargent has been a Non-Executive Director of Origin Energy Limited and is also a Non-Executive Director of Ramsay Healthcare Limited (since December 2021). Mr Sargent's unlisted board activities include Non-Executive Director of The Great Barrier Reef Foundation and Chairman of Origin Energy's philanthropic arm, The Origin Foundation. Mr Sargent was previously Chair of OFX Group Limited (2016 to 2022), and Nonexecutive Director of Veda Group Limited. He is a member of the Risk, Innovation & Development and the People & Culture, Safety Committee.
Dr Tracey Leigh Batten Non-Executive Director Sep 2023
Dr Batten has over 30 years of experience in the healthcare sector in non-executive and executive roles, and medical practitioner and clinical roles. Dr Batten was CEO of Imperial College Healthcare NHS Trust in the UK, St Vincent's Health Australia, Eastern Health and Dental Health Services Victoria. She is a member of the Risk and Innovation & Development Committee.
Mr Gerard Dalbosco Non-Executive Director Jan 2025
Mr Dalbosco had an executive career, most notably at EY, where he held senior leadership roles spanning multiple regions and functions, including Oceania Managing Partner and CEO, Asia Pacific Joint Deputy CEO, and Oceania Managing Partner - Transaction Advisory Services. Mr Dalbosco retired from the EY partnership in 2020. Mr Dalbosco's previous governance roles include Mercy Health & Aged Care, Berry Street Victoria and the Committee for Melbourne. Mr Dalbosco is currently a Non-Executive Director at Medibank Private Ltd and serves as Chair of Melbourne Archdiocese Catholic Schools. He is also Chair of the Gillespie Family Council & Gillespie Family Foundation (founders/owners of Bakers Delight). He is Chair of the Risk Committee and a member of the People & Culture, Safety Committee.
Ms Sarah Butler Non-Executive Director Jan 2026
Ms Butler brings 35 years of expertise in supporting organizations across regulated sectors to achieve global growth, scale their impact and improve diversity and inclusion. Throughout her career, she is in strategic consulting, serving as a partner at Booz Allen Hamilton, Booz & Company and most recently at PwC. At Booz & Company, she held several senior positions, including Global Insurance Leader and Managing Director for Greater China. Ms Butler currently serves as an independent non-executive director of Australian Clinical Labs (ASX: ACL), Lumonus, a private healthtech SaaS company, and health research institute The George Institute for Global Health, where she is Chair of the People & REM Committee. She is also a director of Insurance Manufacturers of Australia Pty Limited (IMA), a joint venture between IAG and RACV focused on personal insurance. Previously, Ms Butler was a director at Booz & Company, where she chaired the Audit & Risk Committee, and at PwC Australia. Ms Butler will serve as a member of Nanosonics Innovation and Development Committee
Mr Matthew Carbines General CounselCompany Secretary May 2023
-
Jason Burriss Chief Financial Officer
-
Sunny Pillai Chief Information Officer
-
Kimberly Hill Chief Marketing Officer
-
Jonathan Burdach Chief Medical Affairs and Scientific Officer
-
Rod Lopez Chief Operating Officer and Regional President for Asia Pacific
-
Jodi Sampson Chief People & Culture Officer
-
Derek Minihane Chief Technology Officer
-
Matthew Carbines General Counsel and Company Secretary
-
Matthew Carbines General CounselCompany Secretary
-
Ronan Wright Regional President for Europe UK and Middle East
-
Ken Shaw Regional President for the United States Canada and Latin America
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 71,862,036 23.67%
J P Morgan Nominees Australia Pty Limited 49,335,638 16.25%
Citicorp Nominees Pty Limited 44,516,283 14.66%
UBS Nominees Pty Ltd 13,266,641 4.37%
BNP Paribas Noms Pty Ltd 13,157,234 4.33%
BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 10,995,075 3.62%
Mr Maurie Stang 8,429,534 2.78%
Mr Bernard Stang 6,882,564 2.27%
Mr Steven Kenneth Kritzler 6,489,737 2.14%
Australian Foundation Investment Company Limited 5,715,556 1.88%
National Nominees Limited 3,834,135 1.26%
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 3,027,451 1.00%
Dr Harry Hirschowitz 2,133,227 0.70%
Mirrabooka Investments Limited 1,747,000 0.58%
Bnp Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 1,275,568 0.42%
Mr Michael Kavanagh 1,256,723 0.41%
HSBC Custody Nominees (Australia) Limited GSCO ECA 1,046,615 0.34%
Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> 908,378 0.30%
First Samuel Ltd Acn 086243567 <Anf Its Mda Clients A/C> 875,716 0.29%
Powerwrap Limited <Escala Sma Trading A/C> 830,576 0.27%

Profile

since

Note